Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis

Bone

Volumn 45, Issue 3, 2009, Pages 460-465

  Liu, Jian Min ^a   Wai chee Kung, Annie ^b   Pheng, Chan Siew ^c   Zhu, Han Min ^d   Zhang, Zhen Lin ^e   Wu, Yi Yong ^f   Xu, Ling ^g   Meng, Xun Wu ^g   Huang, Min Li ^h   Chung, Leung Ping ⁱ   Hussain, Nik Hazlina Nik ^j   Sufian, Seri Suniza ^k   Chen, Jia Lun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^d HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^f BEIJING HOSPITAL   (China)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^h FUDAN UNIVERSITY   (China)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^k UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

more..

Author keywords

Bone mineral density; Osteoporosis; Postmenopausal women; Safety; Strontium ranelate

Indexed keywords

CALCIUM; PLACEBO; STRONTIUM RANELATE; VITAMIN D;

ABDOMINAL PAIN; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; CALCIUM URINE LEVEL; CAUCASIAN; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE URINE LEVEL; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; EOSINOPHIL COUNT; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGICAL PARAMETERS; HIP; HONG KONG; HUMAN; LUMBAR SPINE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALAYSIA; MULTICENTER STUDY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; ZINC BLOOD LEVEL;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES; TREATMENT OUTCOME;

EID: 68049144652     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.05.014     Document Type: Article

References (22)

1. Gullberg B., Johnell O., and Kanis J.A. World-wide projections for hip fracture. Osteoporos. Int. 7 (1997) 407-413
2. Nansa B., and Reginster J.Y. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis. Clin. Orthop. Relat. Res. 443 (2006) 55-60
3. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
4. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
5. Bruyere O., Roux C., Badurski J., Isaia G., De Vernejoul M.C., Cannata J., et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr. Med. Res. Opin. 23 (2007) 3041-3045
6. Bruyère O., Roux C., Detilleux J., Slosman D.O., Spector T., Fardellone P., et al. Relation between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J. Clin. Endocrinol. Metab. 92 (2007) 3076-3081
7. Hui S.L., Gao S., Zhou X.H., Johnston Jr. C.C., Lu Y., Glüer C.C., et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J. Bone Miner. Res. 12 (1997) 1463-1470
8. Lu Y., Fuerst T., Hui S., and Genant H.K. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos. Int. 12 (2001) 438-444
9. Glueer C.C., Blake G., Lu Y., Blunt B.A., Jergas M., and Genant H.K. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporosis. Int. 5 (1995) 262-270
10. Roux C. Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis. Rheumatology 47 (2008) iv20-iv22
11. Roux C., Fechtenbaum J., Kolta S., Isaia G., Cannata Andia J.B., and Devogelaer J.P. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann. Rheum. Dis. 67 (2008) 1736-1738
12. Seeman E., Devogelaer J.P., Lorenc R., Spector T., Brixen K., Balogh A., et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J. Bone Miner. Res. 23 (2008) 433-438
13. Ammann P., Shen V., and Robin B. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J. Bone Miner. Res. 19 (2004) 2012-2020
14. Ammann P., Badoud I., Barraud S., Dayer R., and Rizzoli R. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J. Bone Miner. Res. 22 (2007) 1419-1425
15. Arlot M.E., Jiang Y., and Genant H.K. Histomorphometric and micro-CT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J. Bone Miner. Res. 23 (2008) 215-222
16. Bouxsein M.L., and Delmas P.D. Consideration for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J. Bone Miner. Res. 23 (2008) 1155-1167
17. Ammann P., Badoud I., Barraud S., Dayer R., and Rizzoli R. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J. Bone Miner. Res. 22 (2007) 1419-1425
18. Farlay D., Boivin G., Panczer G., Lalande A., and Meunier P.J. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degrees of mineralisation of bone. J. Bone Miner. Res. 20 (2005) 1569-1578
19. Kendler DL, Adachi JD, Josse RG, Slossman DO, Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporosis Inter 2009;20:1101-1106.
20. Grosso A., Douglas I., Hingorani A., Macallister R., and Smeeth L. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br. J. Clin. Pharmacol. 66 (2008) 689-694
21. Marquis P., Roux C., de la Loge C., Diaz-Curiel M., Cormier C., Isaia G., et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos. Int. 19 (2008) 503-510
22. Coulombe J., Faure H., Robin B., and Ruat M. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem. Biophys. Res. Commun. 323 (2004) 1184-1190